Lv41
510 积分 2021-08-18 加入
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
2个月前
已完结
PCR enhancers: Types, mechanisms, and applications in long-range PCR
3个月前
已完结
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites
4个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
4个月前
已完结
The co-expression of antigen targets as a rationale for ADCs combination in urothelial cancer
5个月前
已完结
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
6个月前
已完结
A guide to artificial intelligence for cancer researchers
6个月前
已完结
Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma
1年前
已关闭
State of the Art of Pathologic and Molecular Testing
1年前
已完结
皖公网安备34019202002308
